BioWorld

Jan. 10, 2006

CancerVax, Micromet Enter $127M Merger Agreement

In a transaction that augments one company's pipeline and gives the other U.S. market access, CancerVax Corp. and Micromet AG signed a definitive merger agreement. (BioWorld Today) Read More

Replidyne Submits NDA For Oral Antibiotic Drug Orapem

More Good Phase III Results With Celgene's Thalidomide

Xytis Series B: $25M For Trials In Schizophrenia, Brain Injury

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...